The use of activated clotting times to monitor heparin therapy during and after interventional procedures
- 1 July 1994
- journal article
- review article
- Published by Wiley in Clinical Cardiology
- Vol. 17 (7) , 357-361
- https://doi.org/10.1002/clc.4960170704
Abstract
Use of the activated clotting time (ACT) was recommended in the mid 1970s to guide administration and reversal of heparin during cardiopulmonary bypass. As the applications of cardiopulmonary bypass spread, so too did the need for more efficient techniques to assess coagulation status. This led to the development of automated ACT measurements. Today, the importance of coagulation and anticoagulation has been further highlighted by recent advances in the field of interventional cardiology. More and more cardiologists are using in‐laboratory bedside coagulation monitoring to assess heparin requirements during interventional procedures such as percutaneous transluminal coronary angioplasty (PTCA). This review focuses on the development of anticoagulation monitoring and provides historic information on the clinical use of heparin. The application of ACTs in the catheterization laboratory and in other clinical situations is discussed, along with alternative methods for bedside assessment of coagulation status. No definite guidelines have been established for ACT monitoring during invasive intravascular procedures; thus its role continues to be refined. in the meantime, the ACT appears to be an extremely useful method for monitoring heparin therapy and the adequacy of anticoagulation.Keywords
This publication has 36 references indexed in Scilit:
- Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparinCatheterization and Cardiovascular Diagnosis, 1992
- Management and immediate outcome of patients with intracoronary thrombus during percutaneous transluminal coronary angioplastyAmerican Heart Journal, 1992
- Validation of a bedside method of activated partial thromboplastin time measurement with clinical range guidelinesThe American Journal of Cardiology, 1991
- Baseline Activated Coagulation Time Should Be Measured After Surgical IncisionAnesthesia & Analgesia, 1990
- Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectorisThe American Journal of Cardiology, 1990
- Percutaneous transluminal coronary angioplasty in the setting of large intracoronary thrombiThe American Journal of Cardiology, 1990
- Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombusThe American Journal of Cardiology, 1990
- Adequate heparinization during PTCA: Assessment using activated clotting timesCatheterization and Cardiovascular Diagnosis, 1989
- HEPARIN DOSES AND MAJOR BLEEDINGSThe Lancet, 1986
- Monitoring heparin therapy in hemodialysis. A report on the activated whole blood coagulation time testsPublished by American Medical Association (AMA) ,1973